WALTHAM, Mass., April  16, 2026  (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc. (NASDAQ:KLRA) (Kailera), an advanced clinical-stage biotechnology company focused on elevating the next era of obesity care, today announced

KLRA

Kailera Therapeutics Announces Pricing of Initial Public Offering

Kailera Therapeutics Sets IPO Price at $16, Raising $625 Million

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>WALTHAM, Mass., April  16, 2026  (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc. (NASDAQ:KLRA) (Kailera), an advanced clinical-stage biotechnology company focused on elevating the next era of obesity care, today announced</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>Kailera Therapeutics, focusing on obesity care, has priced its IPO at $16 per share, aiming to raise $625 million. The shares begin trading on Nasdaq on April 17, 2026, which could position the company for aggressive growth and attract significant attention in the biotech sector.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>Kailera prepares for IPO, pricing shares at $16.00 each.</li><li>39,062,500 shares being offered, totaling gross proceeds of $625 million.</li><li>Trading on NASDAQ to commence on April 17, 2026.</li><li>Underwriters have an option to purchase additional shares within 30 days.</li><li>IPO proceeds will support Kailera&#039;s advanced obesity care initiatives.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>J.P. Morgan (JPM)</strong>: Acting as joint book-running manager, influencing investor perception of KLRA.</li><li><strong>Jefferies (JEF)</strong>: Jointly assisting with the IPO; expected to bring significant investor interest.</li><li><strong>Leerink Partners (LEER)</strong>: Key role in the IPO; their involvement may heighten KLRA&#039;s credibility.</li></ul>
  </section>

  <section data-block="category">
    <h3>Corporate Developments</h3>
    <p>This falls under Corporate Developments as it outlines significant financial moves by KLRA, especially in initiating public offering, which is crucial for future funding strategies and overall growth potential.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>Successful IPO pricing indicates strong market confidence in KLRA.</li><li>IPO proceeds may enhance cash flow for further development in obesity treatments.</li><li>Increased awareness and media coverage around KLRA post-IPO could drive share price.</li><li>Potential exercise of underwriters&#039; option can increase liquidity and support stock price.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>Kailera is offering 39,062,500 shares at $16.00 each.</li><li>Expected gross proceeds are $625 million, excluding underwriter options.</li><li>Trading starts on the NASDAQ on April 17, 2026.</li><li>IPO expected to close on April 20, 2026.</li><li>Underwriters have a 30-day option to purchase an additional 5,859,375 shares.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>KLRA is a buy ahead of its IPO debut, targeting short-term price gains.</p>
  </section>
</section>


<link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css"></link><p>WALTHAM, Mass., April  16, 2026  (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/KLRA">KLRA</a>) (Kailera), an advanced clinical-stage biotechnology company focused on elevating the next era of obesity care, today announced the pricing of its initial public offering of 39,062,500 shares of its common stock at a price to the public of $16.00 per share. All of the shares of common stock are being offered by Kailera. The gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses payable by Kailera, are expected to be $625.0 million, excluding any exercise of the underwriters' option to purchase additional shares. Kailera's common stock is expected to begin trading on the Nasdaq Global Select Market under the ticker symbol "KLRA" on April 17, 2026. The offering is expected to close on April 20, 2026, subject to the satisfaction of customary closing conditions. In addition, Kailera has granted the underwriters a 30-day option to purchase up to an additional 5,859,375 shares of common stock at the initial public offering price less underwriting discounts and commissions.</p>  <p>J.P. Morgan, Jefferies, Leerink Partners, TD Cowen and Evercore ISI are acting as joint book-running managers for the offering. William Blair is acting as lead manager for the offering.</p>  <p>A registration statement on Form S-1 (File No. 333-294690) relating to the offering has been filed with the Securities and Exchange Commission and became effective on April 16, 2026. The offering is being made only by means of a prospectus. Copies of the final prospectus relating to the offering may be obtained from: J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by email at <a href="mailto:prospectus-eq_fi@jpmchase.com">prospectus-eq_fi@jpmchase.com</a> and <a href="https://www.globenewswire.com/Tracker?data=M1NNlCfETXa27g8pLBPNJLineE1NZi00_lka27X1VXVhMpdc3PASylnQJdTdywO8CgZNn6PIXzAs-eEeG603i1Za55Ia3Kc2wL4OD3sfVsjErk_lifV7QQWKQ2dNqmiorC84ZmIqKvPKYA1xOQS9VQ==" rel="nofollow" target="_blank">postsalemanualrequests@broadridge.com</a>; Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, by telephone at (877) 821-7388, or by email at <a href="https://www.globenewswire.com/Tracker?data=b5WVwaZWZVmj6xhz4euhdWQHdJ9_DESBgnj4e8IrEaF0QCzwNo9m8zI487OU8sLZI98KwG3kiIF01apkIuOzLQaczsP-ZhsOpX0siv2XTyg7FuxORkhQsuxgBQmdXAmPwEjtulHi5lCcsg4HIpzKxA==" rel="nofollow" target="_blank">Prospectus_Department@Jefferies.com</a>; Leerink Partners LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, by telephone at (800) 808-7525, ext. 6105, or by email at <a href="https://www.globenewswire.com/Tracker?data=Uq51fEki47FZEBdAWyN72xtGQpVdE1eBf-bbWncRk8KVIFq0nMjj-gwZh1Oh2FjaB8gdXYMlFIkoH9x6kogOsXID5tVRSrbN1BN4nq2tAXU=" rel="nofollow" target="_blank">syndicate@leerink.com</a>; TD Securities (USA) LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by email at <a href="https://www.globenewswire.com/Tracker?data=OQWJ9vVLntM2MbvXjspVwQ0FxH5jtMArRZ746EXYjhh9TGEeOecuhCLOogDleWLsiL417CUjPYWHvXnIrfJFTW2xwe6fVBHyqfyA0VLczZ6bO7D5kXhQsZhCw76WlnEy" rel="nofollow" target="_blank">TDManualrequest@broadridge.com</a>; or Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East 52nd Street, 35th Floor, New York, NY 10055, by telephone at (888) 474-0200, or by email at <a href="https://www.globenewswire.com/Tracker?data=NqG0Q2Twda03CNhFJy-J4nBC_titc8hGbKmZREGIfqpJHGdfrVBFyc_M0Q6X3MkWWRDWgHffbMf5WydKto0jkkPYO7_-HZ3hGIpQDublOkYgD5Zrcy-T-SsL1IrQQVZu" rel="nofollow" target="_blank">ecm.prospectus@evercore.com</a>.</p>  <p>This press release does not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any offer or sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.</p>  <p><strong>Contact</strong><br></br><br></br>Maura Gavaghan<br></br>Vice President, Corporate Communications and Investor Relations<br></br><a href="https://www.globenewswire.com/Tracker?data=70arK_GDr8j6w6ImBf9PUNrftxxVT_MXxDAMSVZj4u_sWSjis_-rjidpylu8GpQo-E_0cROkOEu3qmzWxUfwAIfrwx-1X8OUGrPNHvosIpUuvqX2lg_6yCp1y6Clp3HS" rel="nofollow" target="_blank">maura.gavaghan@kailera.com</a> </p> <img alt="" class="__GNW8366DE3E__IMG" src="https://www.globenewswire.com/newsroom/ti?nf=OTY5MTc3MSM3NTQwODI4IzIyOTUyMTI="></img> <br></br><img alt="" src="https://ml.globenewswire.com/media/NWUwZWFhYjItYzE4OC00NDE3LWJkYzctMThjZTE0ZGVlZjEwLTEzMDY3NjItMjAyNi0wNC0xNi1lbg==/tiny/Kailera-Therapeutics-Inc-.png" referrerpolicy="no-referrer-when-downgrade"></img><p><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/c0b33a3d-0c2b-45b0-ace8-6ff585b41339"><img src="https://ml.globenewswire.com/media/c0b33a3d-0c2b-45b0-ace8-6ff585b41339/small/kailera-logo-png.png" border="0" width="150" height="84" alt="Primary Logo"></img></a></p>

Kailera Therapeutics, focusing on obesity care, has priced its IPO at $16 per share, aiming to raise $625 million. The shares begin trading on Nasdaq on April 17, 2026, which could position the company for aggressive growth and attract significant attention in the biotech sector.

Kailera Therapeutics Announces Pricing of Initial Public Offering

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Corporate Developments

Related News